Affiliation:
1. Gilead Sciences, Inc., Foster City, California, USA
Abstract
Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) are prodrugs of the HIV-1 nucleotide reverse transcriptase inhibitor tenofovir (TFV).
In vivo
, TAF achieves >4-fold-higher intracellular levels of TFV diphosphate (TFV-DP) compared to TDF. Since thymidine analog-associated mutations (TAMs) in HIV-1 confer reduced TFV susceptibility, patients with TAM-containing HIV-1 may benefit from higher TFV-DP levels delivered by TAF. Moreover, the presence of the M184V mutation increases TFV susceptibility during TDF- or TAF-based therapy.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference29 articles.
1. The Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. 2018. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. DHHS/National Institutes of Health, Bethesda, MD. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
2. European AIDS Clinical Society. 2018. Guidelines, version 9.1 (English). European AIDS Clinical Society, Brussels, Belgium.
3. Structure and Function of HIV-1 Reverse Transcriptase: Molecular Mechanisms of Polymerization and Inhibition
4. Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)
5. Primary Infection with Zidovudine-Resistant Human Immunodeficiency Virus Type 1
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献